Comparative Pharmacology
Head-to-head clinical analysis: IBU TAB 200 versus INDOCIN SR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: IBU TAB 200 versus INDOCIN SR.
IBU-TAB 200 vs INDOCIN SR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cyclooxygenase (COX-1 and COX-2) inhibitor, reducing prostaglandin synthesis.
Indomethacin is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2) enzymes, reducing synthesis of prostaglandins, which mediate inflammation, pain, and fever. It also has a direct effect on renal blood flow and platelet aggregation.
200-400 mg orally every 4-6 hours as needed; maximum 1200 mg/day for nonprescription use.
75 mg orally once daily, extended-release capsules.
None Documented
None Documented
2-4 hours (terminal half-life). Short half-life requires frequent dosing for sustained analgesic/antipyretic effect.
Terminal half-life is 4.5 hours (range 2.6-11.2 hours) in young adults; prolonged in elderly (up to 16 hours) and in patients with renal or hepatic impairment.
Renal: 90% as metabolites (glucuronides, hydroxylated derivatives), <10% unchanged. Fecal: <5%.
Approximately 50% renal (as unchanged drug and metabolites, primarily glucuronide conjugates), 33% biliary/fecal. Indomethacin undergoes enterohepatic recirculation.
Category C
Category C
Nonsteroidal Anti-inflammatory Drug (NSAID)
Nonsteroidal Anti-inflammatory Drug (NSAID)